ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 25.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,094 shares of the specialty pharmaceutical company’s stock after selling 1,735 shares during the quarter. Victory Capital Management Inc.’s holdings in ANI Pharmaceuticals were worth $324,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC raised its stake in ANI Pharmaceuticals by 287.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after purchasing an additional 15,790 shares during the last quarter. BNP Paribas Financial Markets boosted its position in ANI Pharmaceuticals by 106.9% during the first quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock worth $1,434,000 after acquiring an additional 10,716 shares during the last quarter. Wakefield Asset Management LLLP purchased a new stake in ANI Pharmaceuticals in the 1st quarter worth approximately $979,000. Sequoia Financial Advisors LLC acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at $600,000. Finally, Lisanti Capital Growth LLC purchased a new position in shares of ANI Pharmaceuticals during the 1st quarter worth $2,218,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

ANIP has been the subject of several analyst reports. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Raymond James upped their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Finally, Truist Financial reaffirmed a “hold” rating and set a $60.00 price target (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.80.

ANI Pharmaceuticals Trading Up 0.7 %

NASDAQ ANIP opened at $60.08 on Tuesday. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81. The company’s 50 day moving average price is $61.00 and its 200 day moving average price is $63.64. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of 37.55 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.07. The firm had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.06 EPS. On average, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.5 EPS for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 14,257 shares of the stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total value of $900,472.12. Following the completion of the sale, the chief operating officer now owns 635,363 shares of the company’s stock, valued at $40,129,527.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the sale, the senior vice president now directly owns 193,226 shares of the company’s stock, valued at $12,258,257.44. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Muthusamy Shanmugam sold 14,257 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total value of $900,472.12. Following the sale, the chief operating officer now owns 635,363 shares of the company’s stock, valued at approximately $40,129,527.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,007 shares of company stock valued at $2,911,790. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.